MentalHealthDaily

Neuromodulation Therapies to Treat Neuroinflammation in Anxiety & Depression (2023 Research)

by GLOOM

The intersection of neuromodulation, neuroinflammation, and their roles in mood disorders like anxiety and depression represents a significant stride in mental health research. This complex interplay underscores the potential of novel therapeutic strategies targeting the brain’s inflammatory pathways, offering new hope for effective management of these pervasive conditions. Highlights: Link Between Neuroinflammation and Mood Disorders: …

Low Dose LSD for Depression Treatment: Preliminary Efficacy (2023 Study)

by GLOOM

Recent research exploring the use of low doses of LSD (Lysergic acid diethylamide) in treating depression marks a significant shift in the psychiatric landscape. This innovative approach seeks to understand and harness the potential therapeutic benefits of psychedelics, which were once stigmatized and largely overlooked in clinical settings. Highlights: Study Design: The research employed a …

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for Rapid Treatment of Suicidal Depression (2023 Study)

by GLOOM

Major depressive disorder (MDD) is a critical public health issue, particularly due to the high risk of suicide associated with it. Traditional treatments often take weeks to show effects and sometimes increase suicide risk in the early phases of therapy. However, a new approach, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), is showing promise in …

Psychedelics for Depression: Targeting the 5-HT2A Receptor & Beyond (2023 Study)

by GLOOM

The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …

Gray Matter Abnormalities in Major Depression & Social Anxiety (2023 Analysis)

by GLOOM

Major depressive disorder (MDD) and social anxiety disorder (SAD) are two of the most prevalent mental health issues facing society today. They often occur together, challenging both patients and healthcare providers. Recent neuroimaging studies have begun to shed light on the unique and overlapping characteristics of these disorders, offering new insights into their complex neurobiology. …

Psychobiotic “Lactobacillus plantarum” (JYLP-326) for Test Anxiety in Students (2023 Study)

by GLOOM

Test anxiety among college students is a significant concern, affecting their mental and physical well-being. A new study suggests that a probiotic/psychobiotic intervention (Lactobacillus plantarum) could significantly alleviate anxiety, depression, and insomnia, with changes observed in the gut microbiota and fecal metabolites. Highlights: Prevalence of Test Anxiety: 20%-40% of college students experience test anxiety, often …

Quetiapine Dosing for Depression Optimized with XGBoost Algorithm (2024 Study)

by GLOOM

Depression is a globally pervasive mental illness that often requires complex treatment strategies. One such strategy involves the use of Quetiapine, an antipsychotic medication, as an augmentation to antidepressants. However, determining the optimal dose of Quetiapine is challenging due to individual variability. A recent study utilizes machine learning techniques to develop a predictive model for …